Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

20201,644 citationsJournal Articlebronze Open Access

Authors

Roy S. Herbst · Yale University

Giuseppe Giaccone · Cornell University

Filippo de Marinis · European Institute of Oncology

Niels Reinmuth · Asklepios Fachkliniken München-Gauting

A. Vergnenègre · Université de Limoges

Carlos H. Barrios · Pontifícia Universidade Católica do Rio Grande do Sul

Masahiro Morise

Abstract

Atezolizumab treatment resulted in significantly longer overall survival than platinum-based chemotherapy among patients with NSCLC with high PD-L1 expression, regardless of histologic type. (Funded by F. Hoffmann-La Roche/Genentech; IMpower110 ClinicalTrials.gov number, NCT02409342.).

Topics & Keywords

Cancer Immunotherapy and Biomarkers Lung Cancer Treatments and Mutations Immunotherapy and Immune Responses

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 383, Issue 14, pp. 1328-1339

DOI: 10.1056/nejmoa1917346

Field-Weighted Citation Impact: 85.86